Selective ERβ agonists, such as MF101 and liquiritigenin, together with histone deacetylase inhibitors, suppress glioma cell proliferation and inhibit tumor growth, highlighting their therapeutic efficacy in glioma treatment strategies [154,155,156]. The gene discussed is ESR2; the disease is central nervous system cancer.